Our Portfolio

Emalex Biosciences

Portfolio Link Arrow emalexbiosciences.com
  • THEME

    Growth Capital

  • STATUS

    active

Emalex Biosciences was created by Paragon Biosciences to develop new treatments for central nervous system disorders. Emalex is in late-stage development of a new class of drug targeting the D1 receptor for patients with Tourette syndrome and other conditions that have limited treatment options. Visit https://emalexbiosciences.com to learn more.

_